Vaccination

Italy approves J&J vaccine, recommends it for over 60s

Credit: Unsplash/CC0 Public Domain

Italy on Tuesday declared the Johnson & Johnson coronavirus vaccine to be “safe” and said it would prioritise its use for people over 60.

The announcement came hours after the European Medicines Agency (EMA) said blood clots should be listed as a “very rare” side effect of the vaccine.

In the light of that ruling, the US-made jab should be considered “definitely safe,” Italian health authorities said in a statement.

It “should be preferentially administered to people over 60 years old” and those particularly at risk from the virus, they added.

The same guidelines were previously issued in Italy for the Anglo-Swedish AstraZeneca jab, which has also been linked to very rare instances of blood clotting.

Separately, Italy’s coronavirus crisis commissioner said a first consignment of 184,000 J&J doses would be distributed across the country starting Wednesday.

The J&J vaccine is seen as easier to administer and transport than some of its rivals, because it requires just one dose and can be stored at warmer temperatures.

But its introduction in Europe was suspended last week after US health regulators said the shot should be paused over blood clot fears.

Italy and other EU countries are keen to make use of it to accelerate their sluggish vaccination campaigns and bring closer a return to some level of normality in people’s lives.


Follow the latest news on the coronavirus (COVID-19) outbreak


© 2021 AFP

Citation:
Italy approves J&J vaccine, recommends it for over 60s (2021, April 20)
retrieved 20 April 2021
from https://medicalxpress.com/news/2021-04-italy-jj-vaccine-60s.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.



Source link

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button

Ad Block Detected

Welcome to Mediexpose, Please support our journalism by allowing ads. With support from readers like you, we can continue to deliver the best. You can support us free by simply allowing ads.